Published in Blood Weekly, May 4th, 2000
"Hemophilia A and B coagulation defects, which are caused by deficiencies of Factor VIII and Factor IX, respectively, can be bypassed by administration of recombinant Factor VIIa", explained H.B. Pollard and colleagues at the Uniformed Services University in Maryland ("In vivo bypass of hemophilia A coagulation defect by Factor XIIa implant," Nature Biotechnology, 2000;18(3):289-295).
Factor VIIa administration isn't a feasible treatment, however, because the substance is too short-lived to have an appreciable effect, according to Pollard...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.